Development

Articles

Evonik offers lipid nanoparticles for gene-based drug development and manufacturing. 

Evonik Supplies Key LNP Technology for Gene-Based Drugs

Behzad Mahdavi, PhD, will join a team of experts in the company’s Science and Technology Group to fast-track the adoption of new development and drug delivery technologies and manufacturing processes and techniques.


Catalent Appoints New Vice President of Open Innovation, Biologics, Cell and Gene Therapy

Eudratec Fasteric is an oral drug delivery technology that offers enteric protection after rapid, homogeneous release for targeting the upper small intestine.

Evonik Launches New Oral Drug Delivery Technology

The Ventofor Combi Fix will be brought into the Turkish market via Bilim’s development program, while the PowdAir Plus DPI is manufactured and commercialized by H&T Presspart under a patent license from Hovione.

Bilim, H&T Presspart, and Hovione Partner to Bring Asthma Product to the Turkish Market

The new site will offer initial design and development, low-volume manufacturing, and scalable high-quality production of wearable drug delivery devices.

Sorrel to Open a New Manufacturing Facility

Agnes Shanley is senior editor of Pharmaceutical Technology.

Manufacturers and the US government are investing heavily in traditional and non-traditional forms and materials to ensure supplies of containers and delivery devices for COVID-19 treatments and vaccines. 


COVID-19: Shoring Up the Drug Delivery Infrastructure

Inovio received a $71-million contract from the US Department of Defense to scale up manufacture of its Cellectra smart device to deliver its DNA vaccine.

Inovio to Scale-Up Manufacture of Intradermal Delivery Device for its COVID-19 Vaccine

The European Commission has granted marketing authorization to the Janssen Pharmaceutical Companies of Johnson & Johnson for Darzalex (daratumumab) subcutaneous formulation to treat adults with multiple myeloma.

EC Grants Marketing Authorization for Subcutaneous Formulation of Daratumumab

The investment will give the company the opportunity to accelerate the development of proprietary boron-10 target drugs while it develops its neutron beam accelerator technology for Boron Neutron Capture Therapy.

TAE Life Sciences to Launch Drug Delivery Program After $30-Million Investment

Kindeva Drug Delivery plans capital investment and jobs growth.